Lyell Immunopharma vs Virax Biolabs
LYEL and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LYEL and VRAX compare
Virax Biolabs grew revenue faster over the last twelve months (96.2% versus −63.4% for Lyell Immunopharma).
Virax Biolabs keeps more of each dollar of sales as profit, with a net margin of −40439% compared with −1701070% at Lyell Immunopharma.
Virax Biolabs scores higher on the StockData Score (9 against 6 for Lyell Immunopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LYEL | VRAX |
|---|---|---|
| Size and price | ||
| Market cap | $350M | – |
| Share price | $14.30 | $0.613 |
| Change, 1 year | −18.9% | −94.7% |
| Change, 5 years | −93.4% | – |
| Beta (5Y) | 1.40 | 1.61 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 23362× | – |
| P/B | 1.8× | – |
| FCF yield | −39.9% | – |
| Growth | ||
| Revenue growth (TTM) | −63.4% | 96.2% (better) |
| Revenue growth, 5Y average | −65.9% | −36.9% (better) |
| Profitability | ||
| Gross margin | – | 61.9% |
| Operating margin | −1783580% | −51515% (better) |
| Net margin | −1701070% | −40439% (better) |
| FCF margin | −933100% | −39264% (better) |
| Return on equity | −97.8% | −75.7% (better) |
| Return on invested capital | −1683% | −388% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.02 | 9.97 (better) |
| Altman Z-score | −8.88 | – |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 48.9% | 0.00% |
| Held by insiders | 45.0% | 63.6% |
| Insider net buying, 12 months | $74.4M | – |
| Short interest, % of float | 10.5% | 3.2% |
Go deeper
- LYEL stock overview
- LYEL income statement
- LYEL valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.